Analysts Rating Review: Esperion Theraptc Cmn (ESPR)

04 May 2018

It has outperformed by 78.31% the S&P500. Therefore 46% are positive. On Thursday, November 16 the stock rating was maintained by Bank of America with "Buy". 86,676 are held by Dimensional Fund Lp. On Wednesday, October 18 the stock rating was maintained by Cowen & Co with "Buy". During the same quarter in the previous year, the business posted ($1.80) EPS. sell-side analysts forecast that Esperion Therapeutics will post -5.61 earnings per share for the current fiscal year. RBC Capital Markets has "Hold" rating and $90.0 target. (NASDAQ:ESPR) on Monday, January 15 with "Buy" rating. (NASDAQ:ESPR) on Wednesday, March 7 with "Buy" rating. See FTI Consulting, Inc. The stock increased 0.33% or $0.06 during the last trading session, reaching $18.13. Halcon Resources Corporation (NYSE:HK) has noticeable measure of stock volatility, for this average true range is an exponential moving average (14 trading days) of the True Ranges. Bank of America upgraded Esperion Therapeutics, Inc. It has outperformed by 7.56% the S&P500.

Investors sentiment decreased to 0.84 in Q4 2017. Its up 0.13, from 1 in 2017Q3.

The stock is trading -44.67% away from its 52 week high of $82.68 and 47.82% far from the stock's low point over the past 52 weeks, which was $30.95. 141 funds opened positions while 552 raised stakes. Rhumbline Advisers holds 0.01% of its portfolio in FTI Consulting, Inc. (NYSE:KR). Cim Investment Mangement Incorporated reported 15,198 shares. 59,654 are held by California State Teachers Retirement Sys. Bingham Osborn And Scarborough Limited accumulated 3,175 shares. Ascend Capital Lc invested in 0.17% or 67,241 shares. Profund Limited Liability Company holds 0.01% or 6,571 shares.

The biotech said that it had a net loss of $1.73 per share for the quarter. Patten Inc holds 1.1% or 33,096 shares in its portfolio. (NYSE:FCN). Wellington Mngmt Gru Llp has invested 0.02% in FTI Consulting, Inc. 6,967 shares were sold by Skiadas Anthony T, worth $346,957. (NYSE:KR). Ajo Ltd Partnership stated it has 0.06% of its portfolio in The Kroger Co. Millennium Ltd stated it has 0.04% of its portfolio in Esperion Therapeutics, Inc. (NYSE:FCN). 5,052 are owned by Cibc Asset Inc.

Since February 28, 2018, it had 0 insider buys, and 1 insider sale for $294,903 activity. The public company has 25.60M shares outstanding now, as well as a market cap of $1.17B. It has a 80.7 P/E ratio.

Latest analyst recommendations could offer little help to investors. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has risen 89.86% since May 3, 2017 and is uptrending. Therefore 55% are positive. Esperion had 17 analyst reports since November 22, 2017 according to SRatingsIntel. Legal & General Grp Inc Public Limited Company accumulated 0.1% or 5.12M shares.

Taking a broader look brokerage firms' analysts on the street with an expectant view have Esperion Theraptc Cmn (NASDAQ:ESPR) high price target of $153 and with a conservative view have low price target of $65. JMP Securities maintained Esperion Therapeutics, Inc. Stifel Nicolaus set a $105.00 target price on shares of Esperion Therapeutics and gave the company a "buy" rating in a research report on Wednesday, March 7th. JP Morgan maintained the stock with "Neutral" rating in Wednesday, February 21 report. The rating was downgraded by Barclays Capital on Wednesday, June 29 to "Equal-Weight". The rating was maintained by Cowen & Co with "Buy" on Tuesday, September 19. RBC Capital Markets maintained Esperion Therapeutics, Inc. The stock has "Neutral" rating by Chardan Capital Markets on Friday, February 26. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the stock.

Investors sentiment decreased to 1.33 in Q4 2017. Its down 0.01, from 0.85 in 2017Q3.

Over the past 50 days, Esperion Therapeutics, Inc. stock's -38.10% off of the high and -21.90% removed from the low.

Other hedge funds have also recently added to or reduced their stakes in the company. Goldman Sachs Gp reported 331,076 shares. JMP Securities now has a $153.0000 TP on the $1.22B market cap company or 234.43% upside potential. The New York-based Price Michael F has invested 0.27% in the stock. Needham upgraded Esperion Therapeutics, Inc. Blackrock has 1.51 million shares.